Normal view

Received — 2 April 2026 ⏭ FDA Press Releases RSS Feed

FDA Press Releases RSS Feed
FDA Approves First Gene Therapy for Severe Leukocyte Adhesion Deficiency Type I FDA
The U.S. Food and Drug Administration today approved Kresladi (marnetegragene autotemcel), the first gene therapy for the treatment of severe Leukocyte Adhesion Deficiency Type I (LAD-I).
27 March 2026 at 06:47

FDA Approves First Gene Therapy for Severe Leukocyte Adhesion Deficiency Type I

27 March 2026 at 06:47

The U.S. Food and Drug Administration today approved Kresladi (marnetegragene autotemcel), the first gene therapy for the treatment of severe Leukocyte Adhesion Deficiency Type I (LAD-I).